Clinical Trial Update: Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the pharmacokinetics, pharmacodynamics, efficacy, and safety of omalizumab in Japanese children aged 6 to 15 with allergic asthma has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Omalizumab (Omalizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Allergic Asthma | Phase 3 | Status: COMPLETED